| Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c 2.4 mg Once-weekly |
Ongoing |
Semaglutide |
3 |
NN9536-7752 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh) ,King Abdulaziz Hospital NG (Al Ahsa), King Abdulaziz Medical City NG (Jeddah) ,King Faisal Specialist Hospital and Research Center (Riyadh) , King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II (RAPIDe-2) |
Ongoing |
Deucrictibant |
2/3 |
PHA022121-C303 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia |
Ongoing |
mRNA-3927 |
1/2 |
mRNA-3927-P101 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| Real-World Evidence non-interventional prospective study for the effectiveness, tolerability and adherence of Asciminib after two previous TKIs in Patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) in Saudi Arabia. (ASC4REAL) |
Ongoing |
Scemblix (Asciminib/ ABL001) |
4 |
CABL001ASA |
King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Medical City NG (Jeddah),King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON) |
Ongoing |
BI 1015550 |
3 |
1305-0031 |
King Abdulaziz Medical City NG (Riyadh) |
| Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia |
Terminated |
Carfilzomib |
2 |
20140106 |
King Fahad Medical City (Riyadh) |
| Netupitant and palonosetron fixed-dose combination versus 5-HT3 receptor antagonists in preventing chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: A randomized, open-label, phase IV trial |
Ongoing |
Netupitant and palonosetron, Granisetron transdermal patch, Ondansetron |
4 |
24-1205 |
King Abdullah Medical City (Makkah) |
| A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) |
Ongoing |
Ultomiris (Ravulizumab) |
4 |
ALX-NMO-50 |
King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Medical City NG (Riyadh),King Fahad Medical City (Riyadh) |
| A PHASE III, PROSPECTIVE OPEN-LABEL, MULTI-CENTER SINGLE ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) PROFILE OF INTRAVENOUS HUMAN NORMAL IMMUNOGLOBULIN (IgG) IN PRIMARY IMMUNODEFICIENCY DISEASE (PID) PATIENTS |
Ongoing |
Golcadomide,BMS-986369 / CC-99282 |
3 |
SKP-LIV_PID_III_2023 |
King Abdulaziz University Hospital (Jeddah), King Fahad Hospital (Jeddah) ,Al-Aziziyah Maternity and Children's Hospital , King Abdulaziz Medical City NG (Jeddah) , King Abdulaziz Medical City NG (Riyadh) |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) |
Ongoing |
Golcadomide,BMS-986369 / CC-99282 |
3 |
CA0731020 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam), King Abdullah Medical Complex (Jeddah) |
